Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Assets for 10 consecutive years, with $480.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets rose 22.41% to $480.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $480.2 million, a 22.41% increase, with the full-year FY2025 number at $480.2 million, up 22.41% from a year prior.
  • Assets was $480.2 million for Q4 2025 at Rhythm Pharmaceuticals, down from $506.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $506.9 million in Q3 2025 to a low of $258.7 million in Q1 2024.
  • A 5-year average of $365.8 million and a median of $368.2 million in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: soared 65.13% in 2021, then tumbled 32.54% in 2022.
  • Rhythm Pharmaceuticals' Assets stood at $329.5 million in 2021, then grew by 16.07% to $382.5 million in 2022, then decreased by 13.0% to $332.7 million in 2023, then grew by 17.89% to $392.3 million in 2024, then rose by 22.41% to $480.2 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Assets are $480.2 million (Q4 2025), $506.9 million (Q3 2025), and $372.7 million (Q2 2025).